News|Articles|January 8, 2025

Long COVID Subsides in a Majority of Healthcare Workers

A survey of this population showed that over a 2 and ½ year period, there was a decrease in post-acute sequelae of SARS-CoV-2 infection (PASC). However, 1% of respondents said they are still dealing with restrictions in their lives.

Undoubtedly, frontline healthcare workers (HCW) took on an enormous burden during the pandemic. According to a study that was conducted from January 1, 2020 through October 12, 2021, a total of 440,044 healthcare workers were reported to have COVID-19, including 1,469 deaths.1

In addition to acute infections and mortality, many HCW have had to deal with lingering symptoms associated with long COVID. Marra et al pointed out that in a group of Brazilian HCW who were diagnosed with acute COVID-19 (7,051), 1,933 (27.4%) of them developed long COVID.2

A new study looked to determine long COVID symptoms in HCW over time. The investigators surveyed HCWs 5 times over a 2 and ½ year period (March 2021, September 2021, June 2022, April 2023, and October 2023.) This was a prospective multicenter HCW-only cohort carried out in Switzerland. They followed HCW who were defined as any hospital employee with or without patient contact. The study included 1,704 HCW and 82% of them were female.3

For the survey, respondents updated their vaccine and infection history and answered questions on PASC-related parameters. To avoid contaminating self-reported long COVID with acute symptoms, questionnaires completed within 28 days of a positive test or within 7 days of vaccination were excluded.

The study’s results were published in the journal, Infection.

“30.7% reported ≥ 1 PASC symptom in 10/2023, with 115 (6.7%) stating to have or have had PASC. Both were most common after wild-type infection compared to other variants,” they wrote. “Overall, 17/115 (15%) indicated relevant/severe restrictions in their daily activities and of 85 (74%) that tried ≥ 1 measure against their symptoms, 69 (81%) reported having benefitted.”3

What You Need to Know

A study in Brazil found that 27.4% of HCWs diagnosed with acute COVID-19 developed long COVID.

A Swiss study surveyed HCWs over a three-year period (2021-2023) to assess long COVID symptoms.

Long COVID symptoms were more common among those infected with the original wild-type SARS-CoV-2 strain than with later variants.

A majority of the HCW did say their symptoms diminished over time. “Over a 30 month period, overall PASC burden in our HCW cohort decreased; although 1% still experience relevant restrictions in their daily life,” the investigators wrote.3

Wild-Type Virus and Long COVID Burden

A longitudinal analysis include 653 HCW, and interestingly, 21% more workers infected with the original wild strain were found to have long COVID symptoms compared to the control group earlier in the pandemic (March 2021). There was a decreasing trend showing only 7% of this group dealing with symptoms 2 and half years later (October 2023).3

“This effect was not evident for non-Wild-type infected HCW,” the authors wrote.3

References
1.Lin S, Deng X, Ryan I, et al. COVID-19 Symptoms and Deaths among Healthcare Workers, United States. Emerg Infect Dis. 2022;28(8):1624-1641. doi:10.3201/eid2808.212200
2.Marra AR, Sampaio VS, Ozahata MC, et al. Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020–2022. Infection Control & Hospital Epidemiology. 2023;44(12):1972-1978. doi:10.1017/ice.2023.95
3. Dörr, T., Strahm, C., Güsewell, S. et al. Burden of post–acute COVID-19 sequelae in healthcare workers and its course over a 30-month period–results from a prospective multicentre cohort. Infection (2024). https://doi.org/10.1007/s15010-024-02418-3

Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.